MedTrace Logo

Study of NGM395 in Adult Participants

NCT04187339 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2021-07-21

No results posted yet for this study

Summary

Study of NGM395 in adult participants.

Conditions

Interventions

BIOLOGICAL

NGM395

NGM395 Dose 1

BIOLOGICAL

NGM395

NGM395 Dose 2

BIOLOGICAL

NGM395

NGM395 Dose 3

BIOLOGICAL

NGM395

NGM395 Dose 4

BIOLOGICAL

NGM395

NGM395 Dose 5

BIOLOGICAL

NGM395

NGM395 Dose 6

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • NGM Biopharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • NGM Study Director · NGM Biopharmaceuticals, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-13
Primary Completion
2020-10-20
Completion
2021-04-22

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04187339 on ClinicalTrials.gov